Biotech company Q BioMed and Jubilant Radiopharma have announced an agreement regarding the distribution of a cancer palliation radiopharmaceutical in the U.S.
Jubilant will distribute Q BioMed's Metastron (strontium-89 chloride injection) metastatic bone cancer palliation drug.
Distribution will begin after the U.S. Food and Drug Administration (FDA) approves Metastron, Q BioMed said.